ARCT - Arcturus Therapeutics Holdings Inc Stock Price, Fair Value and News

26.79USD-0.42 (-1.54%)Market Closed

Market Summary

USD26.79-0.42

Market Closed

-1.54%

ARCT Alerts

Big fall in Revenue (Y/Y)

Big fall in earnings (Y/Y)
Losses in recent quarter

ARCT Stock Price

View Fullscreen

ARCT RSI Chart

ARCT Valuation

Market Cap

721.5M

Price/Earnings (Trailing)

-6.72

Price/Sales (Trailing)

5.79

EV/EBITDA

-3.77

Price/Free Cashflow

73.89

ARCT Price/Sales (Trailing)

ARCT Profitability

EBT Margin

-84.48%

Return on Equity

-40.65%

Return on Assets

-25.62%

Free Cashflow Yield

1.35%

ARCT Fundamentals

ARCT Revenue

Revenue (TTM)

124.5M

Rev. Growth (Yr)

-52.65%

Rev. Growth (Qtr)

23.2%

ARCT Earnings

Earnings (TTM)

-107.3M

Earnings Growth (Yr)

-152.84%

Earnings Growth (Qtr)

-129.07%

Breaking Down ARCT Revenue

Last 7 days

1.0%

Last 30 days

-15.4%

Last 90 days

-32.4%

Trailing 12 Months

-8.9%

How does ARCT drawdown profile look like?

ARCT Financial Health

Current Ratio

3.26

Debt/Equity

0.08

Debt/Cashflow

0.61

ARCT Investor Care

Shares Dilution (1Y)

1.39%

Diluted EPS (TTM)

-4.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	124.5M	0	0	0
2023	281.0M	264.5M	296.2M	166.8M
2022	15.5M	40.6M	51.5M	206.0M
2021	9.0M	8.7M	8.8M	12.4M
2020	19.1M	11.3M	10.3M	9.5M
2019	17.0M	18.3M	19.5M	20.8M
2018	0	0	0	15.8M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Arcturus Therapeutics Holdings Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 25, 2024	chivukula pad	sold	-610,574	35.02	-17,435	chief scientific officer & coo
Mar 19, 2024	chivukula pad	sold	-299,839	35.0075	-8,565	chief scientific officer & coo
Nov 01, 2023	chivukula pad	sold	-93,601	18.7203	-5,000	chief scientific officer & coo
Oct 02, 2023	chivukula pad	sold	-128,062	25.6123	-5,000	chief scientific officer & coo
Sep 01, 2023	chivukula pad	sold	-157,264	31.4527	-5,000	chief scientific officer & coo
Aug 15, 2023	sassine andy	acquired	21,248	17.374	1,223	chief financial officer
Aug 01, 2023	chivukula pad	sold	-174,550	34.91	-5,000	chief scientific officer & coo
Jul 14, 2023	kummerfeld keith c	sold	-243,880	35.00	-6,968	see remarks
Jul 14, 2023	kummerfeld keith c	acquired	62,408	8.95642	6,968	see remarks
Jul 14, 2023	chivukula pad	sold	-875,250	35.01	-25,000	chief scientific officer & coo

Which funds bought or sold ARCT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 08, 2024	Russell Investments Group, Ltd.	new	-	40,321	40,321	-%
May 08, 2024	Bell Investment Advisors, Inc	unchanged	-	85.00	1,284	-%
May 08, 2024	PROFUND ADVISORS LLC	added	31.48	237,135	818,044	0.03%
May 08, 2024	GREAT LAKES ADVISORS, LLC	added	1.58	574,190	7,104,900	0.06%
May 08, 2024	STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM	added	32.33	1,267	211,919	-%
May 08, 2024	ProShare Advisors LLC	new	-	204,781	204,781	-%
May 08, 2024	US BANCORP \DE\	unchanged	-	2,712	40,895	-%
May 07, 2024	Swiss National Bank	unchanged	-	105,728	1,593,940	-%
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	reduced	-75.7	-2,057,010	723,590	-%
May 07, 2024	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-0.28	20,000	323,000	-%

Are Funds Buying or Selling ARCT?

Are funds buying ARCT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ARCT

No. of Funds

Unveiling Arcturus Therapeutics Holdings Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 05, 2024	blackrock inc.	10.2%	2,743,002	SC 13G/A
Feb 13, 2024	vanguard group inc	5.46%	1,458,380	SC 13G/A
Feb 12, 2024	nikko asset management americas, inc.	4.94%	1,320,652	SC 13G/A
Feb 05, 2024	sumitomo mitsui trust holdings, inc.	4.94%	1,320,652	SC 13G/A
Jan 29, 2024	ark investment management llc	7.66%	2,047,687	SC 13G/A
Jan 25, 2024	blackrock inc.	9.0%	2,398,296	SC 13G/A
Jan 25, 2024	state street corp	6.10%	1,629,666	SC 13G/A
Jan 17, 2024	federated hermes, inc.	17.63%	4,711,512	SC 13G/A
Oct 10, 2023	state street corp	6.27%	1,667,925	SC 13G/A
Feb 10, 2023	nikko asset management americas, inc.	5.45%	1,449,060	SC 13G/A

Recent SEC filings of Arcturus Therapeutics Holdings Inc

View All Filings

Date Filed	Form Type	Document
May 08, 2024	8-K	Current Report
May 08, 2024	10-Q	Quarterly Report
Apr 29, 2024	DEF 14A	DEF 14A
Apr 05, 2024	SC 13G/A	Major Ownership Report
Apr 05, 2024	8-K	Current Report
Mar 27, 2024	4	Insider Trading
Mar 21, 2024	4	Insider Trading
Mar 19, 2024	8-K	Current Report
Mar 19, 2024	144	Notice of Insider Sale Intent
Mar 14, 2024	8-K/A	Current Report

Peers (Alternatives to Arcturus Therapeutics Holdings Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.0B	6.8B	9.93%	-6.23%	-7.88	6.87	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.2B	2.0B	-2.86%	-28.22%	-57.69	9.56	75.20%	68.82%
BMRN	15.5B	2.5B	-8.14%	-14.08%	75.54	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-3.24%	-16.29%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	1.09%	107.81%	-9.84	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-22.77%	-53.41%	-12.38	9.86	394.93%	39.61%
AXSM	3.5B	251.0M	1.40%	-8.18%	-11.8	13.94	73.58%	-86.73%
ARWR	3.1B	240.7M	-5.68%	-38.85%	-10.34	12.18	-1.03%	-92.09%
ACAD	2.5B	726.4M	-16.31%	-29.84%	-40.84	3.45	40.45%	71.62%
SMALL-CAP
CPRX	1.9B	411.3M	-0.76%	-10.51%	28.42	4.5	60.38%	-34.49%
NVAX	627.0M	983.7M	1.36%	-50.17%	-1.15	0.64	-50.36%	17.16%
CRBP	467.5M	881.7K	16.76%	369.92%	-13.85	481.06	-77.61%	33.36%
INO	260.8M	4.9M	-4.04%	14.81%	-1.93	53.59	-54.97%	51.71%
IBIO	6.4M	2.1M	-14.75%	74.53%	-0.24	2.14	-13.45%	66.37%

Arcturus Therapeutics Holdings Inc News

Latest updates

Arcturus Therapeutics Holdings Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	23.2%	38,012,000	30,855,000	45,140,000	10,519,000	80,285,000	160,293,000	13,369,000	27,093,000	5,244,000	5,794,000	2,437,000	2,001,000	2,127,000	2,238,000	2,333,000	2,322,000	2,646,000	2,968,000	3,318,000	10,153,000	4,350,000
Operating Expenses	39.3%	68,424,000	49,127,000	64,454,000	65,893,000	65,530,000	38,841,000	50,176,000	49,182,000	55,623,000	43,439,000	56,258,000	55,721,000	59,793,000	33,320,000	23,271,000	12,364,000	12,108,000	13,785,000	10,934,000	10,725,000	10,858,000
S&GA Expenses	-100.0%	-	12,507,000	13,377,000	13,225,000	13,762,000	11,860,000	12,488,000	10,993,000	10,730,000	10,806,000	10,860,000	10,042,000	9,743,000	9,034,000	5,572,000	4,420,000	4,191,000	1,791,000	3,881,000	3,456,000	3,534,000
R&D Expenses	46.3%	53,573,000	36,620,000	51,077,000	52,668,000	51,768,000	26,981,000	37,688,000	38,189,000	44,893,000	32,633,000	45,398,000	45,679,000	50,050,000	24,286,000	17,699,000	7,944,000	7,917,000	11,994,000	7,053,000	7,269,000	7,324,000
EBITDA Margin	-486.6%	-0.80	-0.14	0.36	0.33	0.42	0.06	-3.91	-4.97	-13.04	-16.33	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-100.0%	-	25,000	-	-	2,102,000	228,000	230,000	186,000	169,000	170,000	173,000	172,000	169,000	578,000	-7,000	-48,000	228,000	183,000	168,000	173,000	167,000
Income Taxes	55.3%	368,000	237,000	893,000	600,000	103,000	-	-	-	100,000	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-131.1%	-26,449,000	-11,445,000	-15,329,000	-51,973,000	50,857,000	118,642,000	-35,266,000	-21,563,000	-51,169,000	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	-405.2%	-0.84	-0.17	0.34	0.31	0.40	0.05	-3.95	-5.02	-13.16	-16.48	-	-	-	-	-	-	-	-	-	-	-
Net Income	-129.1%	-26,817,000	-11,707,000	-16,222,000	-52,550,000	50,754,000	117,347,000	-35,266,000	-21,563,000	-51,169,000	-38,663,000	-54,084,000	-54,581,000	-56,346,000	-31,104,000	-21,004,000	-10,263,000	-9,777,000	-10,989,000	-7,433,000	-685,000	-6,884,000
Net Income Margin	-383.5%	-0.86	-0.18	0.34	0.30	0.40	0.05	-2.85	-4.08	-12.83	-16.48	-22.28	-18.74	-	-	-	-	-	-	-	-	-
Free Cashflow	-285.4%	-5,797,000	-1,504,000	-33,387,000	50,453,000	-36,562,000	156,452,000	-44,592,000	-36,443,000	-51,150,000	-43,615,000	-18,419,000	-33,347,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Assets	-2.5%	419	429	458	431	471	450	294	337	342	393	435	449	481	476	323	150	72.00	82.00	87.00	71.00	44.00
Current Assets	-2.8%	376	387	393	385	425	403	247	292	327	379	421	438	470	468	314	142	64.00	74.00	79.00	63.00	42.00
Cash Equivalents	18.3%	345	292	312	323	328	392	238	283	320	370	414	434	467	463	307	136	59.00	71.00	74.00	56.00	37.00
Net PPE	-5.3%	12.00	12.00	13.00	13.00	13.00	12.00	11.00	9.00	8.00	6.00	5.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00
Liabilities	2.6%	155	151	178	145	142	180	148	166	157	165	175	143	129	80.00	61.00	57.00	55.00	56.00	51.00	49.00	31.00
Current Liabilities	40.8%	115	82.00	88.00	90.00	90.00	127	76.00	93.00	107	100	118	71.00	53.00	50.00	28.00	23.00	22.00	21.00	22.00	16.00	13.00
Long Term Debt	-	-	-	20.00	-	-	-	32.00	36.00	39.00	41.00	42.00	56.00	58.00	14.00	15.00	15.00	15.00	15.00	10.00	10.00	10.00
LT Debt, Current	-	-	-	-	-	-	61.00	28.00	27.00	24.00	22.00	-	-	-	1.00	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	20.00	-	-	-	32.00	36.00	39.00	41.00	42.00	56.00	58.00	14.00	15.00	15.00	15.00	15.00	10.00	10.00	10.00
Shareholder's Equity	-5.2%	264	279	280	285	329	270	146	171	185	228	259	306	353	397	262	93.00	17.00	26.00	36.00	22.00	14.00
Retained Earnings	-7.3%	-394	-367	-356	-339	-287	-338	-455	-420	-398	-347	-308	-254	-200	-143	-112	-91.71	-81.44	-71.70	-60.68	-53.25	-44.87
Additional Paid-In Capital	1.9%	659	646	636	625	617	608	601	591	583	576	568	560	553	540	374	185	98.00	97.00	97.00	75.00	58.00
Shares Outstanding	0.3%	27.00	27.00	27.00	27.00	27.00	27.00	26.00	26.00	26.00	26.00	26.00	26.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	692	-	-	-	376	-	-	-	700	-	-	-	701	-	-	-	76.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-783.5%	-5,557	-629	-32,406	50,807	-35,871	160,259	-42,406	-36,821	-49,039	-42,497	-16,653	-32,943	-42,950	-6,632	-15,877	-8,494	-11,858	-7,538	-2,836	9,340	-5,411
Share Based Compensation	14.4%	10,088	8,815	9,269	8,383	8,182	6,530	9,436	7,274	7,371	7,518	6,870	7,540	6,987	2,826	1,988	1,101	849	797	383	403	399
Cashflow From Investing	72.6%	-240	-875	-981	-354	-691	-3,807	-2,186	378	-2,111	-1,118	-1,766	-404	-118	-697	-434	-469	-142	-315	-159	-266	-78.00
Cashflow From Financing	111.7%	2,188	-18,657	21,840	94.00	-27,364	-2,232	-1,220	257	336	230	692	82.00	47,012	163,201	187,223	85,603	118	5,034	21,327	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ARCT Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 38,012	$ 80,285
Operating expenses:
Research and development, net	53,573	51,768
General and administrative	14,851	13,762
Total operating expenses	68,424	65,530
(Loss) income from operations	(30,412)	14,755
Loss from foreign currency	(53)	(328)
Gain on debt extinguishment		33,953
Finance income, net	4,016	2,477
Net (loss) income before income taxes	(26,449)	50,857
Provision for income taxes	368	103
Net (loss) income	$ (26,817)	$ 50,754
(Loss) earnings per share
Basic	$ (1)	$ 1.91
Diluted	$ (1)	$ 1.87
Weighted-average shares used in calculation of (loss) earnings per share:
Basic	26,879	26,555
Diluted	26,879	27,149
Comprehensive (loss) income:
Net (loss) income	$ (26,817)	$ 50,754
Comprehensive (loss) income	(26,817)	50,754
Collaboration Revenue [Member]
Revenue:
Total revenue	32,598	79,729
Grant Revenue [Member]
Revenue:
Total revenue	$ 5,414	$ 556

ARCT Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 288,396	$ 292,005
Restricted cash	55,000	55,000
Accounts receivable	27,057	32,064
Prepaid expenses and other current assets	5,335	7,521
Total current assets	375,788	386,590
Property and equipment, net	11,763	12,427
Operating lease right-of-use asset, net	29,413	28,500
Non-current restricted cash	1,885	1,885
Total assets	418,849	429,402
Current liabilities:
Accounts payable	9,144	5,279
Accrued liabilities	34,770	31,881
Deferred revenue	71,516	44,829
Total current liabilities	115,430	81,989
Deferred revenue, net of current portion	11,795	42,496
Operating lease liability, net of current portion	27,652	25,907
Other non-current liabilities		497
Total liabilities	154,877	150,889
Stockholders’ equity
Common stock, $0.001 par value; 60,000 shares authorized; issued and outstanding shares were 26,917 at March 31, 2024 and 26,828 at December 31, 2023	27	27
Additional paid-in capital	658,628	646,352
Accumulated deficit	(394,683)	(367,866)
Total stockholders’ equity	263,972	278,513
Total liabilities and stockholders’ equity	$ 418,849	$ 429,402

About Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.

CEO	Mr. Joseph E. Payne M.Sc.
WEBSITE	https://arcturusrx.com
INDUSTRY	Biotechnology
EMPLOYEES	170

Arcturus Therapeutics Holdings Inc Frequently Asked Questions

What is the ticker symbol for Arcturus Therapeutics Holdings Inc? What does ARCT stand for in stocks?

ARCT is the stock ticker symbol of Arcturus Therapeutics Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arcturus Therapeutics Holdings Inc (ARCT)?

As of Thu May 09 2024, market cap of Arcturus Therapeutics Holdings Inc is 721.5 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARCT stock?

You can check ARCT's fair value in chart for subscribers.

What is the fair value of ARCT stock?

You can check ARCT's fair value in chart for subscribers. The fair value of Arcturus Therapeutics Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Arcturus Therapeutics Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ARCT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Arcturus Therapeutics Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether ARCT is over valued or under valued. Whether Arcturus Therapeutics Holdings Inc is cheap or expensive depends on the assumptions which impact Arcturus Therapeutics Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARCT.

What is Arcturus Therapeutics Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 09 2024, ARCT's PE ratio (Price to Earnings) is -6.72 and Price to Sales (PS) ratio is 5.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARCT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Arcturus Therapeutics Holdings Inc's stock?

In the past 10 years, Arcturus Therapeutics Holdings Inc has provided -0.134 (multiply by 100 for percentage) rate of return.